Oridonin supplementation in rabbits may help to improve the outcome of induced atherosclerosis via autophagy induction
Effects of oridonin on atherosclerotic progression.
Keywords:
Oridonin, Atherosclerosis, LC3B, Autophagy induction, Rabbits, Anti-inflammationAbstract
Background and aim: Inflammation plays a crucial role in the development of atherosclerotic plague. Oridonin is the major active ingredient of the traditional Chinese medicinal herb Rabdosia rubescens. It is a natural terpenoids that is known as a strong anti-inflammatory supplement by acting as a potent inhibitor of the TXNIP/NLRP3 pathway. Hence, it can reduce the severity of inflammation and improve the outcome of atherosclerotic changes. This study aims to evaluate the anti-inflammatory effects of oridonin in the progression of atherosclerotic plague in rabbits. Methods: Sixty-three male rabbits were included. The rabbits were randomly assigned to one of the three study groups (21 rabbits in each group), normal control diet (NC) fed normal diet for 8 weeks, atherogenic control (AC) fed atherogenic diet (2% cholesterol-enriched diet) for 8 weeks, and oridonin treated group (OT) fed atherogenic diet (2% cholesterol-enriched diet) with oridonin (purity 94%, Sigma-Aldrich, USA) at 20 mg/kg orally daily for 8 weeks. After the end of the study, blood and tissue samples were collected for analysis of various markers of inflammation and atherosclerotic plaque progression. Results: Serum lipids showed a statistically significant improvement in terms of reduction in total cholesterol and low-density lipoprotein (LDL) in the OT group compared to the AC group. This was associated with a significant reduction in serum F2-isoprostane (marker of inflammation) and LC3B (marker of tissue autophagy) between the OT group compared to the AC group. There was also a significant reduction in NLRP3 inflammasome RNA expression in OT group, P<0.001. Conclusions: In animal model, with atherogenic diet, oridonin supplementation can significantly improve the outcome of atherosclerosis by its strong anti-inflammatory action.
References
Xu J, Wold EA, Ding Y, Shen Q, Zhou J. Therapeutic Potential of Oridonin and Its Analogs: From Anticancer and Antiinflammation to Neuroprotection. Molecules. 2018;23(2):474. doi: 10.3390/molecules23020474.
Liu X, Xu J, Zhou J, Shen Q. Oridonin and its derivatives for cancer treatment and overcoming therapeutic resistance. Genes Dis. 2021;8(4):448-62. doi: 10.1016/j.gendis.2020.06.010.
Li X, Zhang CT, Ma W, Xie X, Huang Q. Oridonin: A Review of Its Pharmacology, Pharmacokinetics and Toxicity. Front Pharmacol. 2021;12:645824. doi: 10.3389/fphar.2021.645824.
Gao J, Li C, Wang X, et al. Oridonin attenuates lung inflammation and fibrosis in silicosis via covalent targeting iNOS. Biomed Pharmacother. 2022;153:113532. doi.org/10.1016/j.biopha.2022.113532.
Li J, Bao L, Zha D, et al. Oridonin protects against the inflammatory response in diabetic nephropathy by inhibiting the TLR4/p38-MAPK and TLR4/NF-κB signaling pathways. Int Immunopharmacol. 2018;55:9-19. doi: 10.1016/j.intimp.2017.11.040.
Frostegård J. Immunity, atherosclerosis and cardiovascular disease. BMC Med. 2013;11:117. doi: 10.1186/1741-7015-11-117.
Yanni AE. The laboratory rabbit: an animal model of atherosclerosis research. Lab Anim. 2004;38(3):246-56. doi: 10.1258/002367704323133628.
Hayashi T, Fukuto JM, Ignarro LJ, Chaudhuri G. Basal release of nitric oxide from aortic rings is greater in female rabbits than in male rabbits: implications for atherosclerosis. Proc Natl Acad Sci U S A. 1992;89(23):11259-63. doi: 10.1073/pnas.89.23.11259.
Chen Z, Liu H, Zhao X, et al. Oridonin attenuates low shear stress-induced endothelial cell dysfunction and oxidative stress by activating the nuclear factor erythroid 2-related factor 2 pathway. BMC Complement Med Ther. 2022;22(1):180. doi: 10.1186/s12906-022-03658-2.
Popiolek-Barczyk K, Kolosowska N, Piotrowska A, et al. Parthenolide Relieves Pain and Promotes M2 Microglia/Macrophage Polarization in Rat Model of Neuropathy. Neural Plast. 2015;2015:676473. doi: 10.1155/2015/676473.
He H, Jiang H, Chen Y, et al. Oridonin is a covalent NLRP3 inhibitor with strong anti-inflammasome activity. Nat Commun. 2018;9(1):2550. doi: 10.1016/j.intimp.2017.11.040.
Zhao X, Zhang Q, Wang Y, et al. Oridonin induces autophagy-mediated cell death in pancreatic cancer by activating the c-Jun N-terminal kinase pathway and inhibiting phosphoinositide 3-kinase signaling. Ann Transl Med. 2021;9(13):1084. doi: 10.1038/s41467-018-04947-6.
Kelley N, Jeltema D, Duan Y, He Y. The NLRP3 Inflammasome: An Overview of Mechanisms of Activation and Regulation. Int J Mol Sci. 2019;20(13). doi: 10.3390/ijms20133328.
Lin KH, Li CY, Hsu YM, et al. Oridonin, A natural diterpenoid, protected NGF-differentiated PC12 cells against MPP(+)- and kainic acid-induced injury. Food Chem Toxicol. 2019;133:110765. doi: 10.1016/j.fct.2019.110765.
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Ahmed Sultan, Bassim Mohammad, Najah Hadi, Azhar Al-Shaibany, Anil Philip, Dina Jamil, Hayder Al-Aubaidy
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Transfer of Copyright and Permission to Reproduce Parts of Published Papers.
Authors retain the copyright for their published work. No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.
How to Cite
